In a notable display of contrarian investing, Owls Nest Partners IA has acquired a substantial stake in CorVel (NASDAQ:CRVL), a company whose stock has experienced a significant downturn. The investment fund disclosed a new position of 348,329 shares in CorVel during the last quarter, representing an estimated trade size of $20.06 million, based on quarterly average prices.
A Significant New Position
The disclosure, made via an SEC filing on May 14, 2026, revealed that CorVel now accounts for 6.66% of Owls Nest Partners IA’s reportable assets under management (AUM) as of March 31, 2026. This new holding marks a substantial addition to the fund’s portfolio, which also includes significant positions in TBBK (NASDAQ), ENSG (NASDAQ), TKR (NYSE), WMS (NYSE), and TGLS (NYSE). The quarter-end valuation of the CorVel stake stood at $19.04 million, reflecting both the initial investment and subsequent market movements.
CorVel’s Market Performance and Business Fundamentals
CorVel’s stock has faced considerable headwinds, trading at $62.74 as of market close on May 13, 2026. This price represents a 45% decline over the past year, significantly underperforming the S&P 500, which has gained approximately 28% in the same period. Despite the stock’s weakness, the underlying business appears to be demonstrating resilience.
For fiscal year 2026, CorVel reported a 7% increase in revenue, reaching $959 million. Diluted earnings per share saw a more robust 17% rise, coming in at $2.14. The fourth quarter of fiscal 2026 also showed positive momentum, with revenue climbing 7% to $249 million. The company concluded the fiscal year with a strong balance sheet, holding $233 million in cash and maintaining no debt. Furthermore, CorVel has continued its share repurchase program.
Company Overview and Strategic Focus
CorVel operates as a provider of workers’ compensation, auto, liability, and health solutions. Its services encompass medical fee auditing, claims management, case management, and pharmacy services. The company leverages a technology-driven business model, integrating artificial intelligence (AI) and machine learning to manage healthcare claims and optimize medical cost containment. CorVel serves a diverse client base, including employers, third-party administrators, insurance companies, and government agencies, all seeking to control healthcare-related expenses and enhance care quality.
The company’s strategic emphasis on innovation and operational efficiency positions it as a competitive player in the insurance services sector. Management has highlighted growing demand for CERIS, its healthcare payment accuracy platform, with several significant payer wins expected to drive future revenue visibility as these deployments scale. CorVel continues to invest in key technological areas such as AI, automation, telemedicine, cybersecurity, and data integration across its claims management operations.
Investor Implications and Market Sentiment
The substantial investment by Owls Nest Partners IA suggests a belief that the market has become overly pessimistic regarding CorVel’s prospects. The fund’s move appears to be a contrarian bet on a company that, despite its stock’s sharp decline, continues to execute operationally and deliver growth in earnings and revenue. CorVel’s position at the intersection of insurance, healthcare cost management, and AI-enabled workflow automation, coupled with its consistent cash flow generation and expanding margins, may be the key drivers behind this significant investment.
While the market has punished CorVel’s stock, the company’s financial performance and strategic investments in technology suggest a potential disconnect that Owls Nest Partners IA may be seeking to capitalize on. The fund’s substantial capital allocation indicates a conviction that CorVel’s underlying business value is not being reflected in its current stock price.
